Q3 2024 EPS Estimates for Denali Therapeutics Inc. Increased by Analyst (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Zacks Research upped their Q3 2024 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report issued on Monday, August 19th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings of ($0.62) per share for the quarter, up from their previous estimate of ($0.71). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.77) per share. Zacks Research also issued estimates for Denali Therapeutics' FY2024 earnings at ($2.62) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.67) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.79) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.99) EPS.

Several other brokerages also recently commented on DNLI. JPMorgan Chase & Co. increased their price target on Denali Therapeutics from $28.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, July 10th. HC Wainwright reiterated a "buy" rating and issued a $90.00 target price on shares of Denali Therapeutics in a research note on Thursday, August 15th. Wedbush cut their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. Citigroup upped their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Finally, Stifel Nicolaus dropped their price objective on Denali Therapeutics from $26.00 to $22.00 and set a "hold" rating on the stock in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $39.33.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $1.11 during trading on Thursday, reaching $23.89. The company had a trading volume of 799,180 shares, compared to its average volume of 1,149,935. The firm's 50 day simple moving average is $22.55 and its two-hundred day simple moving average is $20.17. Denali Therapeutics has a one year low of $14.56 and a one year high of $25.34. The company has a market capitalization of $3.41 billion, a PE ratio of -24.71 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.09. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. Denali Therapeutics's quarterly revenue was down 99.7% on a year-over-year basis. During the same quarter last year, the business earned $1.30 earnings per share.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently bought and sold shares of the stock. CWM LLC increased its holdings in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock worth $43,000 after buying an additional 1,376 shares in the last quarter. GAMMA Investing LLC raised its position in Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after purchasing an additional 1,847 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company's stock worth $53,000 after purchasing an additional 807 shares in the last quarter. Fisher Asset Management LLC bought a new stake in shares of Denali Therapeutics during the fourth quarter worth $59,000. Finally, Assetmark Inc. increased its stake in shares of Denali Therapeutics by 65.3% in the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company's stock valued at $76,000 after buying an additional 1,402 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Insider Activity at Denali Therapeutics

In related news, Director Jennifer E. Cook sold 1,458 shares of the company's stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the transaction, the director now directly owns 20,038 shares in the company, valued at $435,425.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the sale, the director now directly owns 34,404 shares of the company's stock, valued at $761,016.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jennifer E. Cook sold 1,458 shares of the company's stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now owns 20,038 shares in the company, valued at $435,425.74. The disclosure for this sale can be found here. Insiders have sold 32,146 shares of company stock worth $710,274 over the last three months. Company insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.